SureTrader
Home > Boards > Canadian > Biotechs > Medicenna Therapeutics (mdna)

Nice move yesterday ..

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
BioSpecialist Member Profile
 
Followed By 106
Posts 1,843
Boards Moderated 2
Alias Born 12/27/07
160x600 placeholder
Medicenna Reports Third Quarter Fiscal 2018 Financial Results PR Newswire (Canada) - 2/12/2018 7:00:00 AM
Medicenna Reports Third Quarter Fiscal 2018 Financial Results PR Newswire (US) - 2/12/2018 7:00:00 AM
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology PR Newswire (Canada) - 11/16/2017 7:00:00 AM
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology PR Newswire (US) - 11/16/2017 7:00:00 AM
Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55 PR Newswire (Canada) - 11/14/2017 7:00:00 AM
Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55 PR Newswire (US) - 11/14/2017 7:00:00 AM
Medicenna Reports Second Quarter Fiscal 2018 Financial Results PR Newswire (Canada) - 11/13/2017 7:00:00 AM
Medicenna Reports Second Quarter Fiscal 2018 Financial Results PR Newswire (US) - 11/13/2017 7:00:00 AM
Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology PR Newswire (Canada) - 11/9/2017 7:00:00 AM
Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology PR Newswire (US) - 11/9/2017 7:00:00 AM
Medicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research Conference PR Newswire (Canada) - 10/31/2017 7:00:00 AM
Medicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research Conference PR Newswire (US) - 10/31/2017 7:00:00 AM
Medicenna Solidifies Superkine Platform with Additional US Patent Issuance PR Newswire (Canada) - 10/24/2017 7:00:00 AM
Medicenna Solidifies Superkine Platform with Additional US Patent Issuance PR Newswire (US) - 10/24/2017 7:00:00 AM
Medicenna Announces Trading on the OTCQX Best Market in the United States PR Newswire (Canada) - 10/18/2017 7:00:00 AM
OTC Markets Group Welcomes Medicenna Therapeutics to OTCQX PR Newswire (US) - 10/18/2017 7:00:00 AM
Medicenna Announces Trading on the OTCQX Best Market in the United States PR Newswire (US) - 10/18/2017 7:00:00 AM
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55 PR Newswire (Canada) - 10/10/2017 10:49:00 AM
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55 PR Newswire (US) - 10/10/2017 10:49:00 AM
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma PR Newswire (Canada) - 9/28/2017 4:30:00 PM
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma PR Newswire (US) - 9/28/2017 4:30:00 PM
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting PR Newswire (Canada) - 9/25/2017 7:00:00 AM
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting PR Newswire (US) - 9/25/2017 7:00:00 AM
Medicenna Appoints Dr. William Li to Board of Directors PR Newswire (Canada) - 9/21/2017 4:00:00 PM
Medicenna Appoints Dr. William Li to Board of Directors PR Newswire (US) - 9/21/2017 4:00:00 PM
BioSpecialist   Thursday, 09/21/17 10:27:25 AM
Re: None
Post # of 1 
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.


Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist